Fund For Hot Korean Biotech Lures Foreign Investors
This article was originally published in PharmAsia News
In its efforts to support South Korean biotech and healthcare firms to successfully advance into overseas markets, the state-run Small and Medium Business Administration (SMBA) will create a joint fund worth $100 million with a U.S.-based venture capital firm to invest in the booming sector.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.